Suvorexant
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
1
Recruiting
1
Completed
2
Sites
2
Countries
1
Endpoints
33
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 33 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 0 of 33 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
No normalized metric codes are available for this asset.
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT04014387Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP) | Suvorexant, Zolpidem Frontotemporal dementia | Study partner/caregiver required | Ph 4 | Completed | 1 | Jun 2025 | 1 | |
| SToP-ADSleep Trial to Prevent Alzheimer's Disease | Suvorexant Alzheimer’s disease | Age ≥65 | Ph 2 | Recruiting | 1 | May 2028 | 1 | |
| NCT02750306Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061) | Suvorexant Alzheimer’s disease | Alzheimer's disease | Ph 3 | Completed | 0 | Sep 2018 | 3 | results |
Showing 1-3 of 3 trials